GlaxoSmithKline and Theravance have announced positive results from two Phase III studies, which showed that patients with Chronic Obstructive Pulmonary...
The FDA has approved Breo Ellipta (fluticasone furoate/vilanterol [FF/VI]), from Glaxo Smith Kline, for the once-daily treatment of asthma in...
GlaxoSmithKline plc and Theravance, Inc. announced the submission of a supplemental New Drug Application (sNDA) to the FDA for a...
GlaxoSmithKline plc and Theravance, Inc. announced initial results from the Study to Understand Mortality and MorbidITy in COPD (SUMMIT) for...
GlaxoSmithKline and Innoviva announced headline results from the pivotal phase III CAPTAIN study of once-daily single inhaler triple therapy Trelegy...